Literature DB >> 35111958

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab.

Catarina O'Neill1, Rui Mendo1, Pedro C Figueiredo1,2.   

Abstract

Entities:  

Keywords:  Gastroduodenitis; Immune checkpoint inhibitors; Immune-related adverse events; Pembrolizumab

Year:  2021        PMID： 35111958      PMCID： PMC8787523          DOI： 10.1159/000515513

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN： 2387-1954


× No keyword cloud information.
  7 in total

1.  Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation.

Authors:  Rui Mendo; Pedro Figueiredo; Luís Mascarenhas
Journal:  GE Port J Gastroenterol       Date:  2020-08-26

2.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.

Authors:  Alice de Malet; Guillemette Antoni; Michael Collins; Emilie Soularue; Lysiane Marthey; Thibaut Vaysse; Clelia Coutzac; Nathalie Chaput; Christine Mateus; Caroline Robert; Franck Carbonnel
Journal:  Eur J Cancer       Date:  2018-11-23       Impact factor: 9.162

4.  Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.

Authors:  Tenglong Tang; Hamzah Abu-Sbeih; Wenyi Luo; Phillip Lum; Wei Qiao; Robert S Bresalier; David M Richards; Yinghong Wang
Journal:  Scand J Gastroenterol       Date:  2019-05-13       Impact factor: 2.423

5.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 6.  Immune checkpoint inhibitor-related luminal GI adverse events.

Authors:  Paul T Kröner; Kabir Mody; Francis A Farraye
Journal:  Gastrointest Endosc       Date:  2019-09-14       Impact factor: 9.427

7.  Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.

Authors:  Charles Dolladille; Stéphane Ederhy; Marion Sassier; Jennifer Cautela; Franck Thuny; Ariel A Cohen; Sophie Fedrizzi; Basile Chrétien; Angélique Da-Silva; Anne-Flore Plane; Damien Legallois; Paul U Milliez; Véronique Lelong-Boulouard; Joachim Alexandre
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.